Organoids as research models for hepatocellular carcinoma

Yu, Justin; Ma, Stephanie

doi:10.1016/j.yexcr.2021.112987

Cited by 11 publications

(14 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The genetic information of these cells indicates mutations and, therefore, contains hints on sensitivity and resistance towards therapy. In addition, CTCs can be used to form organoids, which serve as personalized tumor models to analyze cell signaling and mimic therapeutic approaches in vitro ( 245 – 249 ).…”

Section: Promising New Biomarkers For Clinical Applicationmentioning

confidence: 99%

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common and deadly tumors worldwide. Management of HCC depends on reliable biomarkers for screening, diagnosis, and monitoring of the disease, as well as predicting response towards therapy and safety. To date, imaging has been the established standard technique in the diagnosis and follow-up of HCC. However, imaging techniques have their limitations, especially in the early detection of HCC. Therefore, there is an urgent need for reliable, non/minimal invasive biomarkers. To date, alpha-fetoprotein (AFP) is the only serum biomarker used in clinical practice for the management of HCC. However, AFP is of relatively rather low quality in terms of specificity and sensitivity. Liquid biopsies as a source for biomarkers have become the focus of clinical research. Our review highlights alternative biomarkers derived from liquid biopsies, including circulating tumor cells, proteins, circulating nucleic acids, and exosomes, and their potential for clinical application. Using defined combinations of different biomarkers will open new perspectives for diagnosing, treating, and monitoring HCC.

show abstract

Section: Promising New Biomarkers For Clinical Applicationmentioning

confidence: 99%

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, a significant issue is that a single immortalized cancer cell line only partially captures the tumor profile, and the cell line constantly acquires new mutations during culture. 9,41 The lack of intratumor heterogeneity (ITH) leads to inaccurate reflection of patient responses. Moreover, monolayer cell culture limits cell-cell interactions to a horizontal plane, and the observed nutrient and oxygen gradients of tumors are absent.…”

Section: Primary Liver Cancermentioning

confidence: 99%

“…Moreover, monolayer cell culture limits cell-cell interactions to a horizontal plane, and the observed nutrient and oxygen gradients of tumors are absent. 9 A study by Takai et al demonstrated that immortalized HCC cell lines cultured in 3D form structural features resembling the glandular epithelium observed in vivo, and exhibit increased resistance to chemotherapeutic agents. 91 The cells in 3D also showed increased sensitivity to TGF/β-induced epithelial-mesenchymal transition.…”

Section: Primary Liver Cancermentioning

confidence: 99%

“…7,8 Due to the complex interplay between liver cellular compositions under varying disease etiologies, it has been challenging to construct a robust human model for understanding disease manifestations and treatment responses. 9,10 Most human liver disease models employed thus far have focused on the effects of diseases and chemical agents on inducing hepatocyte injury and cell death. Apart from the cellular changes, the remodeling of the hepatic extracellular matrix(ECM) also plays an integral role during disease progression.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A decade of liver organoids: Advances in disease modeling

Liu¹,

Sheng²,

Ding³

et al. 2023

Clin Mol Hepatol

View full text Add to dashboard Cite

Liver organoids are 3D cellular models of tissue in which cells interact to form unique structures in culture. Since their inception, liver organoids with various cellular compositions, structural features, and functional properties have been described over the past ten years. Methods to create these advanced human cell models range from simple tissue culture techniques to complex bioengineering approaches. These liver organoid culture platforms have been utilized in various liver research fields, including the modeling of liver diseases to regenerative therapy. This review will discuss how liver organoids are used to model diseases, including hereditary liver diseases, primary liver cancer, viral hepatitis, and nonalcoholic fatty liver disease. Specifically, we will focus on studies that utilized two widely adopted approaches: differentiation from pluripotent stem cells and epithelial organoids cultured from patient tissues. These approaches have enabled the generation of advanced human liver models and, more importantly, the establishment of patient-tailored models for evaluating individual-specific disease phenotypes and therapeutic responses.

show abstract

“…Exponentially growing PDO models provide a platform closest to native organs for mapping and exploiting molecular mechanisms of cellular lineage differentiation, organ development, regeneration and diseases [23][24][25][26][27][28]. For malignant progression study, PDOs are 3-D cultures of cancer cells which can be established from a variety of tumor specimens including tissue resections, biopsies, body fluids, circulating tumor cells and pleural effusions from cancers [29][30][31][32][33][34][35][36]. Along with the revolutionary advance, lung organoids were capable of reconstruction of dynamic spatial architecture, molecular identity of cellular components in proximal/distal airways and pathological driver discovery in lung tissue and tumors [37][38][39][40][41][42].…”

Section: Introductionmentioning

confidence: 99%

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized Medicine

Hung¹,

Williams²,

Williams³

et al. 2023

Preprint

View full text Add to dashboard Cite

Lung cancer is the leading cause of global cancer-related mortality resulting in ~1.8 million deaths annually. Systemic, molecular targeted, and immune therapies have provided significant improvements of survival outcomes for patients. However, drug resistance usually arises and there is an urgent need for novel therapy screening and personalized medicine. 3D patient-derived organoid (PDO) models have emerged as a more effective and efficient alternative for ex vivo drug screening than 2D cell culture and patient-derived xenograft (PDX) models. In this review, we performed an extensive search of lung cancer PDO-based ex vivo drug screening studies. Lung cancer PDOs were successfully established from fresh or biobanked sections/biopsy of lung tumors, PDXs, and pleural affusion. PDOs were subject to ex vivo drug screening with chemotherapy, targeted therapy and immune therapy agents. PDOs mainly recapitulated the genomic alterations, transcriptomic landscape and drug sensitivity of primary tumors. Although sample sizes of the previous studies were limited and some technical challenges remained, PDOs showed promise to screen novel therapy drugs. With the technical advance of high throughput, tumor-on-chip, combined microenvironment, and air-liquid interface (ALI), the drug screening using PDOs would serve better for precision care of lung cancer patients.

show abstract

Organoids as research models for hepatocellular carcinoma

Cited by 11 publications

References 114 publications

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice

A decade of liver organoids: Advances in disease modeling

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized Medicine

Contact Info

Product

Resources

About